Introduction
The observation that approximately 50% of malignant melanomas harbor mutations in the BRAF gene has triggered intensive efforts to develop inhibitors of mutant BRAF, including vemurafenib and dabrafenib. Although the introduction of these drugs has revolutionized the treatment of BRAF-mutant (BRAF MUT ) melanoma patients, sustained benefit is limited by intrinsic and acquired resistance. The major mechanism of acquired resistance appears to involve reactivation of MAPK signaling, and indeed dual BRAF/MEK inhibition has improved clinical responses compared with single-agent treatment (1). Nevertheless, BRAF/MEK inhibitor combination therapy fails to provide a curative treatment option for patients with BRAF-mutant melanoma most likely due to concurrent genetic alterations conferring codependencies. In accordance with a complementary role of PTEN, PTEN LOF alterations were identified in approximately 40% of BRAF MUT melanoma and were shown to promote Braf-driven metastatic melanoma in a genetically engineered mouse model (2) . Furthermore, PTEN LOF alterations are associated with BRAF inhibitor resistance in cellular models and in patients as well as decreased progression-free survival upon dabrafenib treatment (3) (4) (5) . Similarly, decreased PTEN protein levels were found to predict for vemurafenib insensitivity, highlighting the urgent need for the optimization of targeted therapies for this genetic context (6) .
PTEN encodes a lipid phosphatase that antagonizes PI3K activity by dephosphorylating phosphatidylinositol-3,4,5-trisphosphate. Class IA PI3Ks are heterodimeric lipid kinases composed of a p85 regulatory subunit and one of three catalytic subunits, namely p110a, p110b, or p110d (PI3Ka, PI3Kb, or PI3Kd). Whereas PI3Ka and PI3Kb are ubiquitously expressed, expression of PI3Kd has been reported to be largely restricted to the hematopoietic system. In contrast with this, interrogation of the Cancer Cell Line Encyclopedia (CCLE) and associated mRNA expression profiles revealed significant expression levels of all three isoforms in the majority of cell lines derived from diverse lineages (7) . Nevertheless, PTEN LOF cancers and cell lines of different lineages have been shown to specifically depend on PI3Kb (8) (9) (10) . In this study, we demonstrate for the first time the exquisite dependence of PTEN LOF melanoma on the PI3Kb isoform. Although PI3Kb inhibitors were only partially efficacious, using an unbiased RNAi approach, we identified a homogeneous pattern of chemosensitization to PI3Kb inhibition with PI3Ka, insulin-like growth factor receptor 1 (IGF1R), and components of the MAPK pathway as top hits in PTEN LOF /BRAF MUT melanoma. We subsequently confirmed that dual inhibition of PI3Ka/b was required to permanently block PI3K signaling and that addition of PI3Ka/b inhibitors strongly synergized with MAPK pathway inhibitors. In comparison with direct targeting of PI3Ka, anti-IGF1R antibodies, which presumably block receptor tyrosine kinase (RTK)-mediated PI3Ka activation in the tumor tissue only, were as efficacious, but did not lead to the induction of glucose abnormalities. These data provide a strong rationale for the first-line combination of MAPK pathway inhibitors with panPI3K or PI3Kb/IGF1R inhibitors to overcome intrinsic and acquired resistance to BRAF inhibitors in PTEN LOF /BRAF MUT melanoma.
Materials and Methods

Cell lines and reagents
Cell lines were obtained from and cultured as recommended by the ATCC, Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, and Health Science Research Resources Bank. Authenticity was confirmed by single-nucleotide polymorphism fingerprinting, and cells were cultivated less than 20 passages before use.
High-throughput cell line profiling and manual cell proliferation assays
The sensitivity profiles of melanoma lines used for this study were extracted from a high-throughput profiling approach described previously (7) . Manual determination of the antiproliferative effect of compounds or compound combinations was performed as described previously using methylene blue or resazurin staining as readout (11, 12) . Detailed information is summarized in Supplementary Materials and Methods.
Synthetic lethality pooled shRNA screen Lentiviral supernatants of barcoded custom library (Cellecta) of approximately 170,000 shRNAs targeting approximately 7,500 genes (divided into three sublibraries) were produced according to the manufacturer's recommended protocols. After infection and puromycin selection, cells were cultivated AE1 mmol/L rac-KIN-193 at a minimal representation of 1,000 cells/shRNA for five population doublings. The representation of each shRNA barcode was measured by next-generation sequencing on an Illumina HiSeq platform. Hits for each panel of cell lines were identified as described in Supplementary Materials and Methods.
Immunoblotting and coimmunoprecipitation assays
Immunoblotting and coimmunoprecipitation experiments were done according to standard methods. Detailed information and a comprehensive list of antibodies are provided in Supplementary Materials and Methods.
Reverse-phase protein array
Reverse-phase protein array (RPPA) was performed as described previously (13) . In brief, cells were seeded in duplicate in 96-well plates at an appropriate density, and the following day, they were treated with serial compound dilutions for 1 hour, washed with ice-cold PBS, and lysed in CLB96 lysis buffer (Bayer Technology). Pulverized tumor samples were processed accordingly.
Proteomics
Immunoprecipitates were separated by SDS-PAGE and in-gel digested using a Trypsin/Lys-C Mix (Promega). Peptides were analyzed by LC-MS/MS (LTQ OrbiTrap Elite; Thermo) as described previously (14) , using spectral counting as a proxy for the protein quantity.
Cell death and apoptosis assay
Induction of cell death was determined in triplicates on an Array Scan VTI platform (Cellomics) using 2 mg/mL propidium iodide (PI) (Life Technologies) and 1 mg/mL Hoechst33342 (Sigma). Induction of apoptosis was determined in triplicates by Annexin V/PI staining (Life Technologies) according to the manufacturer's flow cytometry protocol.
Tumor growth inhibition in vivo
WM-266-4 cells (2 Â 10 6 ) were injected subcutaneously into the flanks of nude mice. At a tumor volume of 200 to 300 cm 3 , mice were treated with the indicated compounds. Detailed information, including analysis of glucose/insulin levels, is provided in Supplementary Materials and Methods.
Results
PTEN
LOF melanomas specifically depend on PI3Kb To determine whether specific compound mechanisms selectively impair the growth of PTEN LOF melanoma cells, we compared the activity of 1397 compounds for their effect on the viability of 14 PTEN LOF and 27 PTEN WT melanoma lines from the CCLE based on their activity area (combined measure of compound potency and efficacy) as described elsewhere (7) . This analysis revealed that PI3Kb inhibition best discriminates among 390 different modes of action tested between PTEN LOF and PTEN WT melanoma lines ( Fig. 1A ; Supplementary Table S1 ). In contrast, PI3Ka, PI3Kd, PI3Kg, or panPI3K inhibitors did not score significantly as selectively active compounds toward PTEN LOF melanoma lines. Interestingly, sensitivity to PI3Ka-selective inhibitors was detected primarily in PTEN WT lines, but these compounds did not pass the significance cutoff (P < 0.01; data not shown).
Accordingly, treatment of the PTEN LOF /BRAF MUT melanoma cell line RVH-421 with the PI3Kbi rac-KIN-193, but not with the selective PI3Kai BYL719, led to a reduction in Akt phosphorylation within 1 hour in a dose-dependent manner (Fig. 1B) . Quantitative analysis using RPPA validated this finding in three different cell lines ( Fig. 1C; Supplementary Fig. S1A ). Short-term treatment with two different PI3Kbi's (rac-KIN-193/TGX-221) reduced Akt phosphorylation similarly to the panPI3Ki (GDC-0941), whereas a PI3Ka inhibitor reduced Akt phosphorylation only at high concentrations where it is also active against other PI3K isoforms.
To test whether inhibition of Akt phosphorylation led to growth inhibition, the antiproliferative effect of these compounds was determined in a panel of 
α-IRS2 
/BRAF
MUT melanoma lines. After five population doublings (AEPI3Kbi), the relative abundance of each individual shRNA was determined by deep sequencing (Fig. 2A) . Redundant siRNA activity (RSA) scores of drug-treated and untreated control samples were compared using Limma's linear model within each genotype to identify gene products that were selectively required in the presence of PI3Kbi in the PTEN
LOF
/BRAF
MUT cells only (15) . PIK3CA, IGF1R, BRAF, MAP2K1, and MAPK1 were identified as top sensitizers to PI3Kb inhibition in a genotype-selective manner with a marked distinction from any other hit in this unbiased approach (Fig. 2B) .
The above data suggested that PI3Ka and IGF1R signaling were attenuating the response to PI3Kb inhibitors. To further test this notion, and to ask whether a PI3Kai would hence act synergistically with a PI3Kbi in PTEN
MUT lines were treated with a PI3Kbi and a PI3Kai in a matrix combination setting (Fig. 2C) . Although single-agent treatment with PI3Kai did not affect proliferation, combination with PI3Kbi1 led to an enhanced antiproliferative effect at all concentrations tested (Fig. 2C ). Synergy scores (SS > 2) demonstrated that the combination of both drugs acted in a robust synergistic manner. The structurally diverse PI3Kbi2 GSK-2636771 yielded similar results, indicating that these synergistic effects are likely on-target. In conclusion, the combination of specific small-molecule inhibitors recapitulated the synthetic lethal interaction identified by RNAi in the chemosensitization screen.
Small-molecule inhibition of PI3Kb triggers the recruitment of p85 to IRS2 in PTEN LOF /BRAF MUT melanoma The fact that PI3Kai activity was only observed in combination with a PI3Kbi raised the possibility that PI3Kb inhibition leads to the activation of PI3Ka. Activation of PI3Ka is regulated by membrane recruitment of the p110a/p85 complex to tyrosinephosphorylated RTKs or their adaptor proteins via the interaction of p85 SH2 domains with phosphorylated YXXM motifs (16) (17) (18) . In order to examine PI3Ka recruitment to RTKs or adaptor proteins, we next studied the interaction of p85 with phosphotyrosine-containing proteins upon PI3Kbi treatment. Immunoblot analysis of p85 coimmunoprecipitates using a pTyr antibody revealed one specific signal upon PI3Kbi treatment in RVH-421 cells (Fig. 3A) . Label-free mass spectrometric analysis of these immunocomplexes identified 20 proteins that were enriched upon PI3Kbi treatment (Supplementary Table S2 ). Among these, only the adaptor protein insulin receptor substrate 2 (IRS2) that mediates the activation of signaling pathways in response to ligand stimulation of cell surface receptors is reported to be Tyr-phosphorylated and harbors 6 YXXM motifs, therefore being a potent activator of PI3K (16, 19) . Subsequent, direct coimmunoprecipitation assays confirmed that PI3Kb inhibition induced a robust p85/IRS2 interaction (Fig. 3B) . These studies also demonstrated PI3Kbi-induced tyrosine phosphorylation of IRS2 with concomitant reduction of pIRS2 S731 levels and the consequential change in IRS2 protein migration in the SDS gel (20) . Timecourse experiments revealed that the interaction was detectable within 30 minutes of treatment ( Supplementary Fig. S2A ).
To explore the correlation of PI3K pathway inhibition and p85/ IRS2 interaction in more detail, RVH-421 cells were treated with a panel of PI3K inhibitors of different isoform specificities (Fig. 3C) . Both the PI3Kbi and the panPI3Ki reduced phosphorylation of Akt, S6, NDRG1, a known substrate of the mTORC2-regulated kinase SGK, and IRS2 (Fig. 3C, bottom; ref. 21 ), whereas the PI3Kai did not affect PI3K signaling in this cell line. In keeping with this, treatment with both the PI3Kbi and the panPI3Ki triggered the p85/IRS2 interaction, whereas the PI3Kai did not (Fig. 3C, top) . In contrast, in the PTEN
WT
/BRAF
MUT cell line A-375, the PI3KaI, but not the PI3KbI, caused the same consequences as described before for the PI3Kbi in the PTEN
LOF
/BRAF
MUT setting (Fig. 3D) .
In conclusion, our data support the notion that PI3K signaling is reactivated upon PI3Kb inhibition in PTEN
LOF
/BRAF
MUT melanoma by recruitment of PI3K to an activated RTK via the adaptor molecule IRS2.
Small-molecule inhibition of mTOR, PDK1, and Akt relieves feedback inhibition on IRS2 in PTEN LOF /BRAF MUT melanoma In addition to the role of PI3Kb in activating the classical PI3K pathway, PI3Kb exhibits Akt/mTOR-independent functions, including the regulation of autophagy (22) . To investigate whether classical PI3Kb downstream signaling accounts for the induction of p85/IRS2 interaction, we asked whether inhibition of mTOR, PDK1, and Akt with selective small molecules would also trigger the p85/IRS2 interaction. The catalytic mTORi AZD8055, the allosteric mTORC1i RAD001 ( Fig. 4A; Supplementary Fig.  S2B ), the catalytic PDK1i GSK-2334470 ( Fig. 4B ; Supplementary  Fig. S2C ), and MK2206, which inhibits Akt membrane localization ( Fig. 4C; Supplementary Fig. S2D ), all induced p85/IRS2 complex formation in a dose-dependent manner.
These data strongly suggest that PI3Kb inhibition leads to the loss of feedback inhibition mediated by Ser/Thr kinases, including Akt, mTORC1, and S6K and, subsequently, to the IRS2-dependent recruitment of PI3Ka through activated RTKs.
Small-molecule inhibition of IGF1R signaling potentiates PI3Kb inhibitor activity in PTEN LOF /BRAF MUT melanoma As IGF1R was found among the highest scoring sensitizers to PI3Kb inhibition (Fig. 2B) , we speculated that IGF1R was the sole RTK mediating the reactivation of PI3K signaling upon PI3Kbi treatment. In agreement with this, AEW541 treatment (IGF1Ri) blocked PI3Kbi-induced p85/IRS2 interaction in a dose-dependent manner (Fig. 5A ). In keeping with previous reports showing an increase in RTK expression levels by PI3K inhibition (23), longterm PI3Kbi treatment led to an increase in IGF1R levels in the four PTEN
LOF
/BRAF
MUT models tested ( Supplementary Fig. S3 ). To further validate IGF1R inhibition as a sensitizer to PI3Kb inhibition, cell viability was determined upon treatment with this combination. Whereas the IGF1Ri had only minor antiproliferative effects, a fixed concentration of the compound enhanced PI3Kbi efficacy at all concentrations tested ( Fig. 5B ; Supplementary Fig. S4A ). Furthermore, matrix combination assays confirmed the synergistic activity of IGF1Ri with two structurally distinct PI3Kbi's, but not the PI3Kai, in two PTEN LOF /BRAF MUT lines ( Fig.  5C; Supplementary Fig. S4B ). PanPI3Ki treatment also led to synergistic effects, albeit less significant due to its stronger efficacy as single agent. Importantly, the selectivity of this synergy with PI3Kbi's in the genetic context of PTEN LOF was underscored by the lack of combination activity in the PTEN
WT
/BRAF
MUT melanoma cell line A-375 (Supplementary Fig. S4C ).
These data indicate that IGF1R inhibition acts in combination specifically with PI3Kb inhibitors to block proliferation of PTEN
LOF
/BRAF
MUT melanoma by interfering with the reactivation of PI3K signaling through PI3Ka.
Concomitant inhibition of PI3Kb, IGF1R, and MAPK signaling leads to a complete and sustained pathway blockade and induction of cell death in PTEN
LOF
/BRAF
MUT melanoma In keeping with the known dependence of BRAF MUT melanoma on the MAPK pathway, the pooled shRNA screen identified shRNAs targeting key nodes of MAPK signaling (BRAF, MAP2K1, and MAPK1) among the strongest sensitizers to PI3Kb inhibition (Fig. 2B) . Indeed, the two PI3Kbi's and the panPI3Ki showed strong synergy upon combination treatment with the BRAFi (LGX818) or the MEKi (MEK162) while the PI3Kai did not ( Fig. 6A and B; Supplementary Fig. S5A and S5B ). As expected, synergy was not observed in the PTEN WT background (Supplementary Fig. S5C and S5D) . Thus, our data support the notion that adding PI3Kb inhibitors to MAPK pathway inhibitors in PTEN LOF / BRAF MUT melanoma elicits a robust and specific combinatorial activity.
In a next step, the impact of IGF1R-mediated activation of PI3Ka on the ability of a PI3Kbi to permanently block the PI3K/ mTOR pathway was assessed in two cell lines ( Fig. 6C ; Supplementary Fig. S6A and S6B ). Although treatment with the PI3Kbi for 2 hours efficiently blocked PI3K/mTOR signaling, a rebound after 72 hours of treatment was detected (lanes 1/2 and 11/12). Loss of activity due to compound instability was excluded as the compound had been refreshed appropriately. Dual PI3Ka/b or panPI3K inhibition prevented this PI3K/mTOR signaling rebound (lane 16; Supplementary Fig. S7A ). Consistent with an exclusive role for IGF1R in PI3Ka activation, the IGF1Ri (or an anti-IGF1R antibody; Supplementary Fig. S6B ) substituted for the PI3Kai in preventing this rebound (lane 17). The elevated MAPK signaling in this BRAF MUT setting might interfere with PI3K/ mTOR signaling by regulation of the activity of the TSC1/2 complex and phosphorylation of S6 at Ser235/236 by its effector RSK (24) (25) (26) . Indeed, concomitant inhibition of MEK/PI3Kb/ PI3Ka led to a significant decrease not only in Erk but also in S6 phosphorylation when treatment was continued for 72 hours. This sustained MAPK/PI3K/mTOR blockade led to the induction BRAFi Fig. 6D; Supplementary Fig. S7B ). Most importantly, however, further addition of either the PI3Kai or the IGF1Ri was associated with an even more pronounced increase in the fraction of early and/or late apoptotic cells underscoring the need for sustained concomitant blockade of MAPK and PI3K signaling in order to maximize impact on cell viability in this genetic context ( Fig. 6D; Supplementary Fig.  S7B ). In addition, matrix combination assays revealed that PI3K pathway inhibition using PI3Kbi/PI3Kai or PI3Kbi/ IGF1Ri combinations also enhanced the antiproliferative effect of the current BRAF/MEK inhibitor regimen in the setting of PTEN LOF /BRAF MUT and shifted the response toward cell death ( Supplementary Fig. S8A and S8B) .
Taken together, these results show that, in PTEN LOF /BRAF MUT melanoma, the benefit of adding PI3Kb to MAPK pathway inhibition is limited due to reactivation of PI3Ka by relieving a feedback inhibition on IGF1R signaling (Supplementary Fig.  S9 ). Thus, sustained and concomitant inhibition of PI3Kb together with PI3Ka or IGF1R and MAPK signaling is necessary to achieve complete long-term pathway inhibition and maximize induction of cell death.
Concomitant inhibition of PI3Kb, IGF1R, and MAPK signaling blocks tumor growth in vivo Due to the dominant role of PI3Ka in glucose homeostasis, the substitution of PI3Ka with IGF1R inhibitors provides the unique opportunity to circumvent dose-limiting on-target side effects of PI3Ka inhibition in insulin-sensitive tissues. Therefore, the efficacy and effects on glucose homeostasis of PI3Kai or IGF1Ri treatments in combination with PI3Kbi/BRAFi were determined in the PTEN LOF /BRAF MUT xenograft model WM-266-4. Contrary to the in vitro findings, the PI3Kai and PI3Kbi were almost equally efficient in inhibiting tumor growth, most likely due to the reported antiangiogenic effect of PI3Ka inhibition (27) . The inhibition of both isoforms individually boosted the effect of the BRAFi, but dual PI3Ka/b inhibition increased the efficacy of BRAFi treatment even further. Interestingly, although IGF1R inhibition (anti-IGF1R antibody) substituted for PI3Ka inhibition in the blockade of tumor growth (Fig. 7A) , there were profound differences in their effects on glucose homeostasis. As expected, PI3Kai treatment resulted in hyperglycemia that was particularly pronounced in the triple PI3Kai/PI3Kbi/BRAFi combination. Strikingly, no effects on insulin signaling and body weight were observed in any of the anti-IGF1R antibody treatment arms (Fig.  7B, data not shown) . Pharmacokinetics analysis confirmed the expected exposures excluding possible drug-drug interactions (data not shown).
In summary, these data demonstrate a clear improvement of efficacy of sole BRAF inhibition in the PTEN
LOF
/BRAF
MUT melanoma background by concomitant dual PI3Ka/b blockade using either direct PI3Ka or IGF1R inhibitors and provide a strong rationale to test such combinations in humans.
Discussion
Here, we have demonstrated for the first time that PTEN LOF in the setting of BRAF MUT melanoma causes selective sensitivity to PI3Kb inhibitors. However, the major limitation of PI3Kb as a drug target in this genetic setting is the immediate rebound of PI3Ka signaling. Therefore, concomitant inhibition of PI3Ka is required to achieve sustained PI3K pathway blockade and enhance the apoptotic response upon treatment with the current BRAF/MEK inhibitor regimen.
In parallel with our findings, recent studies revealed that the contribution of individual isoforms to PI3K signaling upon PTEN LOF is highly context dependent. Although PTEN LOF tumors and cancer derived from prostate and breast lineage specifically depend on PI3Kb signaling (8) (9) (10) , in PTEN LOF cell lines and tumors derived from the endometrial lineage, dual inhibition of PI3Ka/b is required to reduce cell viability or tumor growth, especially in a Kras-mutant background (28, 29) . Similarly, both PI3Ka/b contribute to the PTEN hamartoma tumor syndrome (30) , whereas T-cell acute lymphoblastic leukemia driven by PTEN LOF relies on the activity of PI3Kg/d in line with the predominant role of these isoforms in the hematopoietic lineage (31) . These observations underscore the need for the determination of isoform dependency in different indications as well as indepth analysis of coexisting genetic alterations. Indeed, recent studies revealed a mechanism of actively induced compensation by the various PI3K isoforms (32, 33) . Similarly, while we observed a primary sensitivity to PI3Kb inhibitors in our melanoma panel and a trend toward PI3Kd sensitivity (Fig. 1A) , combination of PI3Kbi with PI3Kai was necessary to inhibit PI3K signaling upon long-term treatment. In contrast, long-term treatment with PI3Kdi did not synergize with PI3Kbi to robustly inhibit PI3K signaling, but dual PI3Kd/a inhibition caused mild reduction of pAkt ( Supplementary Fig. S3 ). In contrast with our findings, a recent study using genetically engineered murine models and three cell lines distinct to ours excluded a role of the PI3Kb isoform in PTEN
LOF
/BRAF
MUT melanoma but demonstrated the sole involvement of PI3Kd/a instead (34) . Taken together, these findings indicate that the isoforms' interplay and the corresponding tumor dependency is diverse and highly context specific. Thus, depending on the adaptive input from the upstream RTKs and G protein coupled receptors, PTEN loss will amplify the signal of different class IA PI3K isoforms. This suggests clinical strategies that would either require the combined use of isoform-specific inhibitors in specifically selected subsets of PTEN LOF /BRAF MUT melanoma patients or the use of panPI3K inhibitors across the whole PTEN
LOF
/BRAF
MUT melanoma population. However, systemic PI3Ka inhibition will ultimately lead to the induction of on-target dose-limiting toxicities that are even Mice from efficacy study were sacrificed after 4 hours after last dose. Blood glucose and plasma insulin levels were assessed and are represented as mean AE SEM (n ¼ 5-6 per time point).
Ã , P < 0.05 vs. vehicle controls; #, P < 0.05 vs. triple combination (ANOVA on ranks and post hoc Dunn or Tukey test). PI3Kbi, GSK2636771; PI3Kai, BYL719; BRAFi, LGX818; and IGF1Ri, figitumumab-like antibody.
exacerbated when combined with MEK inhibitors. Alternative scheduling regimens or targeting the mechanism of PI3Ka reactivation in the tumor tissue specifically might circumvent this problem. Our data provide evidence that in PTEN LOF /BRAF MUT melanoma PI3Kb inhibition triggers PI3Ka activation via IGF1R and that IGF1R inhibition indeed substitutes for PI3Ka inhibition to block tumor growth, providing a unique opportunity to minimize the induction of glucose abnormalities. In contrast with several reports pointing to highly heterogeneous resistance mechanisms to inhibitors of PI3K/mTOR involving a diverse set of RTKs (35, 36) , we identified exclusively and reproducibly shRNAs targeting IGF1R as sensitizers of PI3Kb inhibition across a panel of PTEN
LOF
/BRAF
MUT melanoma lines by blocking the reactivation of PI3Ka signaling.
Activation of PI3K signaling via the IGF1R has been shown to contribute to the emergence of resistance to targeted therapies in a variety of human cancers, including BRAF MUT melanoma treated with a BRAF inhibitor (37) (38) (39) (40) . To achieve increased efficacy of therapy and prevention of resistance, it might therefore be beneficial to improve patient stratification beyond BRAF MUT status and extend the standard treatment of MAPK inhibition upfront with PI3K pathway inhibitors, especially in a setting where PTEN is already lost. Based on the results presented here, however, we speculate that in patients with BRAF MUT and concomitant PTEN LOF , a combination of MAPK pathway inhibition with dual PI3Ka/b inhibitors or with panPI3K inhibitors may be more effective than sole combination of MAPK pathway with PI3Kb inhibitors. One of the major concern with such strategies is, however, the induction of changes in glucose homeostasis due to blockade of the PI3Ka isoform in insulin-sensitive tissues (41), leading to dose-limiting hyperglycemia. Therefore, the observation that PI3Ka was exclusively activated by IGF1R in PTEN LOF / BRAF MUT melanoma provided the unique opportunity to successfully replace the PI3Ka inhibition by a combination of IGF1R and PI3Kb inhibitors, thereby minimizing on-target side effects on insulin-sensitive tissues (42) .
The pharmaceutical industry has heavily pursued the development of various PI3K and MAPK pathway inhibitors with distinct modes of action over the last decade. The availability of these compounds together with the data presented in this work strongly argues for the initiation of preclinical and clinical studies to evaluate the potential long-term benefit for patients with PTEN-
LOF
/BRAF
MUT melanoma treated with a combination of MAPK pathway inhibitors together with pan PI3K or PI3Kb and IGF1R monoclonal antibodies.
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